Settlement Agreement: Catalyst Pharmaceuticals and SERB S.A. have reached a settlement with Lupin Pharmaceuticals, ending a patent lawsuit regarding Firdapse (amifampridine) 10 mg tablets.
Patent Protection: As per the settlement, Lupin is prohibited from selling its generic version of Firdapse in the U.S. until at least February 25, 2035, pending FDA approval.
Lawsuit Dismissal: The agreement includes the dismissal of all current patent lawsuits between Catalyst/SERB and Lupin concerning Firdapse patents in the U.S. District Court for New Jersey.
Market Reaction: Following the announcement, shares of Catalyst Pharmaceuticals (CPRX) increased by 2.75%.
CPRX
$23.67+Infinity%1D
Analyst Views on CPRX
Wall Street analysts forecast CPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CPRX is 34.00 USD with a low forecast of 33.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast CPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CPRX is 34.00 USD with a low forecast of 33.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 24.000
Low
33.00
Averages
34.00
High
35.00
Current: 24.000
Low
33.00
Averages
34.00
High
35.00
Oppenheimer
Leland Gershell
Outperform
maintain
$32 -> $33
2025-11-07
Reason
Oppenheimer
Leland Gershell
Price Target
$32 -> $33
2025-11-07
maintain
Outperform
Reason
Oppenheimer analyst Leland Gershell raised the firm's price target on Catalyst Pharmaceuticals to $33 from $32 and keeps an Outperform rating on the shares. The firm notes the company reported Q3 total revenue of $148.4M, coming in well above its/consensus estimates of $136M/$137M and driving non-GAAP net income of $86.1M.
Citi
Buy
maintain
$31 -> $33
2025-11-07
Reason
Citi
Price Target
$31 -> $33
2025-11-07
maintain
Buy
Reason
Citi raised the firm's price target on Catalyst Pharmaceuticals to $33 from $31 and keeps a Buy rating on the shares. The firm sees the upper end of the company's 2025 outlook as potentially achievable following the Q3 report.
Baird
Joel Beatty
Buy
Maintains
$28 → $32
2025-03-03
Reason
Baird
Joel Beatty
Price Target
$28 → $32
2025-03-03
Maintains
Buy
Reason
Baird raised the firm's price target on Catalyst Pharmaceuticals to $32 from $28 and keeps an Outperform rating on the shares. The firm updated its model following its Q4 report as its Firdapse and Agamree are poised for a strong 2025.
HC Wainwright & Co.
Andrew Fein
Strong Buy
Reiterates
$35
2025-02-28
Reason
HC Wainwright & Co.
Andrew Fein
Price Target
$35
2025-02-28
Reiterates
Strong Buy
Reason
About CPRX
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The Company markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
